Funding Rounds
HepaRegeniX Series B round, January 2020
HepaRegeniXSmall molecule MKK4 inhibitors to treat acute and chronic liver diseases
Summary
Stage: Series B
Raised Amount: $12.10M
Raised Date: 2020-01-24
Stage: Series B
Raised Amount: $12.10M
Raised Date: 2020-01-24